Biomarkers for Traumatic Brain InjuryEditat de Alan H.B. Wu, W. Frank Peacock
en Limba Engleză Paperback – 11 Jul 2020
Biomarkers for Traumatic Brain Injury provides a comprehensive overview on the selection and implementation of serum-based biomarkers for traumatic brain injury. The book presents an economic analysis for implementing TBI biomarkers into clinical practice. In addition, it discusses the analytical tools needed to implement TBI biomarkers, including specifications for testing instruments and interpretative software. Neurologists, emergency department physicians, intensivists, and clinical laboratorians will find this book a great resource from which to familiarize themselves with the issues and processes regarding TBI biomarkers.
Approximately 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year with over 250,000 hospitalizations and 50,000 deaths. There has been a significant rise in interest in diagnosing mild concussions, particularly in the sports world. While imaging has been the gold standard, these procedures are costly and not always available. There is great potential in using serum-based biomarkers, hence the book seeks to enlighten readers on new possibilities.
- Offers strategies for the selection and implementation of traumatic brain injury biomarkers
- Discusses the importance of autoantibodies and post translational modifications for TBI
- Covers the analytical tools needed to implement TBI biomarkers, including the specifications for testing instruments and interpretative software
Dimensiuni: 191 x 235 mm
Greutate: 1.12 kg
Editura: ELSEVIER SCIENCE
Public țintăresearchers in neurologic diseases, neurologists, emergency department physicians, intensivists, and clinical laboratorians
1. Scope of the problem
Pathophysiology of TBI 2. Blood brain barrier pathophysiology 3. Apoptosis 4. Autoimmune response 5. Post translational modifications in TBI
TBI biomarkers in medical practice 6. Correlation and complementation to neural imaging techniques 7. Diagnostic need in the emergency department 8. Diagnostic need for the intensive care unit 9. Outpatient risk assessment following TBI 10. Physiologic TBI biomonitoring 11. TBI therapeutics
Classical and novel TBI Biomarkers 12. Classical TBI biomarkers 13. Low molecular weight metabolomics markers 14. Autoantibodies for risk stratification 15. Novel biomarkers including citrillinated G-fab, neurogranin, and brain derived neurotropic factor
Analytical and clinical laboratory testing consideration 16. Strategies for biobanking 17. Analytical performance goals 18. Sensitivity immunoassay testing platforms 19. High sensitivity mass spectrometry 20. Alternate sample matricies for biomarker testing (e.g., CSF, oral fluids) 21. Algorithms and interpretative software 22. The regulatory environment for TBI biomarkers 23. Economic analysis and justification for TBI biomarkers